INTRODUCTION
Prostate adenocarcinoma (PCa) is the most common malignancy in Western countries and the second leading cause of cancer-related deaths in men. [1] [2] [3] Despite improvements in diagnosis, surgical techniques, and drugs, survival rates of PCa have improved little, and most PCa-related deaths are as a result of metastatic castration-resistant prostate cancer (mCRPC), which progresses and metastasizes after surgical or medical castration. An often underrecognized late manifestation of PCa is the development of neuroendocrine prostate cancer (NEPC) in the form of small-cell or large-cell type, also called treatment-related NEPC (tNEPC), which is considered to be a hormone-refractory subtype of prostate cancer. [4] [5] This tumor does not secrete prostatespecific antigen (PSA) and is a highly aggressive subtype of prostate cancer characterized by the following clinical features: unresponsiveness to hormone therapy, presence of lytic bone lesions, rapid disease progression, presence of visceral metastases, marked prostatic enlargement, and disproportionately low PSA levels in the setting of metastatic disease.
The development of tNEPC is estimated to cause approximately 25% of the nearly 34,000 cases of lethal prostate cancer per year in the United
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States. 6 However, data from autopsy studies suggest that the incidence of NEPC may be significantly underestimated. 7 The amount of neuroendocrine differentiation increases with disease progression and correlates with patient exposure to long-term androgendeprivation therapy. Preclinical studies also support the idea that transformation from PCa to tNEPC is promoted by androgendeprivation therapy and may arise as a mechanism of resistance. [8] [9] [10] [11] Therefore, with the introduction of novel, highly potent androgen receptor-targeted therapies in the clinic, the incidence of tNEPC can be expected to increase.
Because of the rarity of this disease, its under-recognition, and a general lack of biopsy diagnoses for advanced disease, few articles on NEPC progressing from conventional PCa have been published. 12 Until now, the majority of these cases have been documented in single case reports and small series, thereby limiting our ability to make definitive conclusions regarding clinical course, prognosis, and the most effective treatment. In addition, risk factors related to survival and time-to-development of tNEPC in PCa patients are yet to be elucidated.
In this study, we have systematically reviewed the literature for individually documented cases of tNEPC to comprehensively characterize the clinical and pathologic features and outcomes of tNEPC and to identify risk factors related to survival rates after NEPC diagnosis (NEPCS) and time from initial diagnosis of PCa to NEPC diagnosis (TTNEPC) in PCa patients.
PATIENTS AND METHODS

Search Strategy
We searched the following databases through October 2013: MEDLINE, EMBASE, the Chinese CNKI and Wanfang, the Japanese KURENAI and J-STAGE, and ASCO Annual Meeting and other specialty meeting abstracts. No language restrictions or time limits were applied. We also checked reference lists of relevant articles and review articles. We contacted corresponding authors of studies that lacked sufficient information to complete data collection. For publications that included updates and additions to prior publications, the most recent ones were included. Searching strategies, databases, and date ranges are described in the Data Supplement (online only).
Inclusion and Exclusion Criteria
Two reviewers (H.T.W. and Y.H.Y.) independently screened the identified abstracts for eligibility and retrieved full articles for detailed assessment. Studies were eligible if outcomes data (NEPCS and/or TTNEPC) were reported for patients with a histopathologically confirmed NEPC (small-cell or large-cell type, pure NEPC, or mixed adenocarcinoma and NEPC) after a prior history of PCa.
NEPC was diagnosed according to the WHO classification 2004. NEPC of large-cell type fulfilled the following criteria: neuroendocrine morphology, mitotic rate greater than 10 per 10 high-power fields, necrosis, and positive immunohistochemical staining for one or more neuroendocrine (NE) markers. NEPC of small-cell type fulfilled the morphologic criteria for small-cell carcinoma as established for lung tumors, specifically, small-to medium-sized cells with a minimal amount of cytoplasm and hyperchromatic, overlapping nuclei with no or few nucleoli.
We excluded studies for which no outcomes data could be obtained. Reports that did not specify the TTNEPC or NEPCS until the last follow-up or death, rendering time-to-event end points calculations impossible, were also excluded. Reports were excluded if the inclusion criteria could not be verified. Studies that were excluded for these reasons are listed in the Data Supplement.
Data Extraction
Two 
Statistical Analysis
TTNEPC was defined as the time from the date of initial diagnosis of PCa to the date of diagnosis of NEPC. NEPCS was defined as the time from the date of diagnosis of NEPC to the date of death. In the absence of confirmation of death, survival time was censored at the last date the patient was known to be alive.
Data on patient demographics, tumor characteristics, and treatment modalities were summarized using descriptive statistics. The associations between these factors and the TTNEPC and NEPCS were evaluated using univariable and multivariable Cox regression models, by computing the robust sandwich estimates of the covariance matrix. The hazard ratio (HR) of death and its 95% CI were calculated for each factor. The median survival time and survival curves were generated using the Kaplan-Meier method. Generally, P Ͻ .05 (two-sided) was considered statistically significant. Statistical analyses on survival were performed using SPSS version 16.0 (SPSS, Chicago, IL). The robust sandwich estimates of the covariance matrix in Cox regression models were performed using SAS version 9.1.3 (SAS Institute, Cary, NC). The institutional review board of Tianjin Medical University has deemed studies using anonymized, publicly available data (such as those used herein) to be exempt from review. 
RESULTS
Search Results and Characteristics of the Included Studies
Our search strategy yielded a total of 773 articles. Of these, only 82 articles were relevant reports of patients with tNEPC following PCa. After reviewing these articles, we found 54 that reported histopathologically confirmed tNEPC and that fulfilled the inclusion criteria (Fig 1) .
4-5,13-62 Of these 54 suitable articles, 52 case reports or case series 4-5,13-14,18,20-28,30-31,35-57,59-60,62 (with 89 patients) were in English, six were in Japanese 15-17, [33] [34] 61 (with eight patients), and two were in Chinese 29,32 (with 11 patients), giving a total of 108 patients. We also found two review articles in Japanese 19,58 (with 15 patients). A total of 123 prostate cancer patients with tNEPC were identified from the literature (Fig 1) ; their detailed clinical characteristics are listed in the Data Supplement. Baseline characteristics are summarized in Table 1 and Table 2 .
Time From Initial Diagnosis of PCa to NEPC Diagnosis
The median TTNEPC was 20 months (range, 1 to 144 months; Fig 2) . In multivariable analyses, the Gleason score was significantly associated with shorter TTNEPC (HR, 1.66; 95% CI, 1.04 to 2.64; P ϭ .032; Table 3 ).
Survival After NEPC Diagnosis
The median rate of survival after NEPC was 7 months (range, 0.5 to 63 months; Fig 2) . In multivariable analyses, the number of organs showing metastatic disease at NEPC was significantly associated with shorter NEPCS (HR, 3.31; 95% CI, 1.62 to 6.76; P ϭ .001). Type of treatment after NEPC was significantly associated with longer NEPCS, with HRs of 0.66 (radiotherapy v palliative therapy [PT]: 95% CI, 0.45 to 0.96; P ϭ .034), 0.38 (chemotherapy v PT: 95% CI, 0.17 to 0.85; P ϭ .018), and 0.29 (chemoradiotherapy v PT: 95% CI, 0.11 to 0.76; P ϭ .012; Table 4 ). Abbreviations: NED, neuroendocrine differentiation; PCa, prostate adenocarcinoma; PSA, prostate-specific antigen. 
DISCUSSION
Studies focusing specifically on tNEPC developing from PCa are rare and are limited by small sample sizes. To the best of our knowledge, this is the first report investigating prognostic factors related to TTNEPC and NEPCS in PCa patients. The median value for NEPCS of 7 months suggests that the prognosis remains poor despite scientific progress in this field. The most significant aspect of our study is that it may increase awareness of the importance of the tNEPC among physicians and pathologists. Considerable attention needs to be paid to the presence of tNEPC developing from previous adenocarcinoma, on account of its implications for treatment and prognosis. tNEPC may present with special clinical characteristics. About 80.3% of tNEPC had rapidly progressive castration-resistant prostate cancer (CRPC) with disproportionately low PSA values; 8.1% have Cushing's syndrome (Table 2 ; Data Supplement). In addition, visceral metastases and high levels of serum NE markers, such as chromogranin A (CgA), neurone-specific enolase (NSE), and gastrin-releasing peptide, were common. Therefore, the diagnosis of NEPC may be facilitated by features of rapidly progressive CRPC with low PSA, paraneoplastic syndrome, and visceral metastases, including liver and brain, or high levels of serum NE markers. Careful clinical assessment of CRPC patients suspected of having NEPC is thus important. A repeat biopsy in patients with pre-existing prostate cancer is advised to rule out a diagnosis of NEPC, given its implications for treatment and prognosis. 63 The diagnostic criteria for NEPC of small-cell type is controversial in clinical practice. According to the WHO criteria of 2004, 64 the diagnosis is primarily based on histologic morphology, though it can be supported or confirmed by immunohistochemistry (IHC) of NE
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Time From PCa Diagnosis to NEPC Diagnosis (months) markers. A working committee on the molecular biology and pathologic classification of NEPC assembled by the Prostate Cancer Foundation on July 31, 2013, also emphasized the importance of morphologic criteria. 65 Typically, one or more NE markers (CgA, synaptophysin, NSE, and CD56) were positive by IHC. However, the IHC profiles were not consistent, and NEPC can be negative for NE markers and can express PSA in occasional cases. 66 In our series, 77.2% of tNEPCs were NE-marker positive. Only eight of 123 tNEPCs failed to demonstrate positivity for at least one NE marker (20 patients had no material available for IHC staining). In addition, all tNEPCs behaved aggressively in our series regardless of NE-marker expression patterns, which contributed to a more confident diagnosis of NEPC. Therefore, morphology remains the gold standard in the diagnosis of NEPC. However, morphologic interpretation alone suffers from subjectivity and significant interobserver variability. In fact, the NEPC diagnostic criteria have evolved over time with an increasing recognition of CRPC. Some clinicians have speculated that prostate cancers that display clinical features associated with small-cell carcinoma morphology, a syndrome initially dubbed anaplastic, have a common underlying biology. Several recent studies supported the view that CRPC that display clinical features associated with small-cell carcinoma morphology also share its responsiveness to chemotherapy and poor prognosis.
67-69 Accordingly, anaplastic clinical criteria had been defined to more broadly encompass morphologically heterogeneous CRPCs (from typical histology of usual high-grade prostatic adenocarcinoma to pure or mixed small-cell carcinoma or large-cell neuroendocrine carcinoma with similar clinical phenotype). Epstein et al 65 proposed further modifications to the anaplastic clinical criteria in an effort to increase diagnostic sensitivity in NEPC patients. With a greater understanding of CRPC, it is anticipated that tumors with this clinical category will be further classified in molecularly defined pathologic subsets. The understanding of their biology will help to establish an optimal nomenclature encompassing the clinical and pathologic spectrum of these tumors.
Regarding the factors that were prognostic of survival after diagnosis of NEPC, multivariable analysis found the type of treatment after tNEPC and number of organs with metastatic disease at tNEPC to be important. Regarding type of treatment, the mainstay is systemic therapy (mostly chemotherapy), and this, in combination with radiation (or surgery), is used for clinically localized disease or for palliation of individual sites of metastatic disease.
12, 70 To our knowledge, the optimal treatment strategy for NEPC has yet to be determined. This uncertainty is largely because of the rarity and highly aggressive phenotype of this entity. In our study, treatments including chemoradiotherapy, chemotherapy, and radiotherapy were associated with longer NEPCS, with chemoradiotherapy achieving the best rates of survival (Table 4 ). This suggests the importance of treatment strategy, though it might represent a selection bias of patients, because the patients who were treated generally had a better medical condition. This is in agreement with other observations in neuroendocrine carcinoma of nonprostatic origin. The scientific literature evaluating the treatment outcomes of patients with neuroendocrine carcinoma of nonprostatic origin revealed that aggressive, dose-intensified chemotherapy regimens offer therapeutic benefit, albeit one potentially associated with increased toxicity. 71 Other studies have proposed that multimodality therapy using a combination of chemotherapy and radiotherapy may offer an improved therapeutic result. 72 Quite apart from the type of treatment, another important prognostic factor for NEPCS is the number of organs with metastatic disease at NEPC. Our study found that patients with a high burden of metastatic disease (Ն three sites) had significantly worse rates of survival compared with patients with fewer than three sites. This suggests that the number of organs with metastatic disease may reflect the biologic progression of the tumor, with oligometastatic disease being less aggressive than its more disseminated counterpart. The prognostic impact of the number of organs with metastatic disease in NEPC has been studied in a previous retrospective series. 70 Papandreou et al 70 reported that the number of organs with metastatic disease involved was an independent and a poor prognostic factor for survival after NEPC (HR, 2.21; 95% CI, 1.01 to 4.87; for per each log increase).
The median TTNEPC of 20 months suggests that NEPC usually occurs late in the course of PCa and is therefore a late manifestation of systemic disease and most often occurs in patients after extensive therapy with hormone and/or chemotherapy. With NEPC occurring as the result of poor systemic disease control, predicting the timing of NEPC development may provide a rationale for early intervention and treatment of NEPC, considering the prognostic stratification of this rare disease.
This study found the Gleason score on multivariable analysis to be predictive of shorter TTNEPC, which was significantly less for patients with Gleason Ն 8, as opposed to Gleason of fewer than eight tumors. This is in accordance with a previous study 70 that investigated the importance of pathologic grade in 36 NEPC patients (treatmentrelated, n ϭ 27; de novo, n ϭ 9). Papandreou et al 70 found that poorly differentiated tumors were correlated with shorter intervals to develop NEPC compared with well or moderately differentiated tumors, although the data were not statistically significant (18 v 42.5 months).
There are some limitations in our study. The major one is the inclusion criteria for tNEPC. Pathologic criteria were used in the study; however, these criteria are difficult enough to standardize in a multicenter study and it would be even more difficult in a retrospective study using only published information. As all the patients were indeed retrospectively selected from the literature, there was no opportunity to review the original pathology slides. Moreover, because NECP is uncommon and under-recognized, and given the retrospective nature of the data collection, as well as the limited information provided in the literature, the statistical results should be interpreted cautiously. For example, the absence of association for some factors with survival could be attributed to the small numbers of patients and insufficient statistical power. Further, any of the reported effects found in this analysis might be an artifact owing to a variance in settings between case reports/series. Nevertheless, the findings from our study are still valuable for better understanding the disease processes of tNEPC and the factors affecting the time to development and survival of patients with this rare disease.
The systematic evaluation of the literature reveals that significant progress has been made in understanding the molecular mechanism of NEPC development. Beltran et al 63 recently showed that gene amplification of AURKA and MYCN were present in approximately 65% of primary prostate adenocarcinoma specimens that subsequently develop NEPC after androgen-deprivation therapy and in approximately 90% of the corresponding metastatic tumors. In contrast, the same amplifications were only present in 5% of 169 unselected prostate adenocarcinoma samples. These results indicated that AURKA and MYCN could play important roles in the development of smallcell neuroendocrine carcinoma of the prostate. Lapuk et al 73 found that decreased expression of REST transcription complex may drive the emergence of the neuroendocrine phenotype, favoring a model of adenocarcinoma transdifferentiating to NEPC. As the molecular mechanism for NEPC becomes better understood, individualized therapy may be possible. For example, preclinical studies with AURKA inhibitor PHA-739358 (danusertib) demonstrated that this kinase antagonist has specific inhibitory effects on the growth of neuroendocrine tumor cells in cell culture and xenograft models. 44 This has led to the development of the Aurora A kinase inhibitor for patients with NEPC, which is now being evaluated in phase II clinical trials in histologically confirmed NEPC. 63 Although there is a great deal of emerging data on NEPC, more molecular work is warranted to increase our understanding of this important disease that may eventually help find novel therapies.
In conclusion, tNEPC is an often under-recognized late manifestation of PCa with poor prognosis. Our study found that Gleason score was the only independent factor contributing to TTNEPC. Once NEPC is diagnosed, type of treatment and number of metastatic organs were the most important factors related to survival. Additional studies are necessary to identify specific molecular features of the disease or treatment that may be associated with tNEPC.
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